300 



Index 



Leukeran, in lymphoproliferative disorders, 258 

 Leukocyte count, average normal, 148 

 in follicular lymphoma, giant, 212 



in lymphatic leukemia, chronic, 212, 213, 216, 



219, 224 

 therapy affecting, 204 

 Leukocytes, effects on inflammatory exudates. 

 80 

 neutrophilic, phagocytic powers of, 73 

 Leukocytoid lymphocytes, 281-282 

 Leukolymphosarcoma, lymphoid cells in, 33 

 Leukosis, fowl, 163 



experimentally transmitted, 163 

 Life span of lymphocytes, 67-69, 156 

 Lipase activity, 42 



Lipid granules, electron microscopy of, 57. 60 

 Lipid histiocyte. 261 

 Lipids, in lymphocytes, 39-41 



in reticulum cells. 264 

 Litwins, J., 147 



Liver, in feline malignant lymphoma, 174 

 in follicular lymphoma, 183, 184, 207 

 hematopoiesis in, 23 

 in Hodgkin's disease, 241 

 in lymphatic leukemia, acute, 225 



chronic, 212. 213, 216, 219, 222 

 in lymphoblastoma, 178 

 lymphocytes reentering, 68 

 in lymphosarcoma, 225 

 of urodeles, 23 

 Lobulation of lymph node, in Hodgkin's para- 

 granuloma, 232 

 Lobulation of nucleus, in Iymphoblast, leu- 

 kemic, 276 

 in lymphocytes, 280 



after radiation, 125 

 in plasma cell, 284 



in reticulum cell, in Hodgkin's disease, 239, 

 246, 268 

 leukemic blood-forming, 273 

 Loci), L., LOO 

 Loew, M.. 232, 236 

 Low, F. N., 54-65 



Lumb, G., 202, 205, 207, 230, 245. 262 

 Lung, lymphocytes reentering, 68 



mediastinal lymphoma spreading to, 230, 251 

 Lupus erythematosus, disseminated, plasmacv- 



tosis in, 285 

 Lymph nodes, acid phosphatase in, 12 

 adrenalectomy affecting, 112 

 alkaline phosphatase in, 12 

 antibodies in, 46, 82 



antibody production b\ cells, and anaphy- 

 laxis reaction. 10 I 

 biopsy, in Hodgkin's disease, 211 

 in canine malignant lymphoma, 169 

 in iat scratch disease, 264 

 cell transfer, ami hemagglutinin production, 

 106 



Lymph nodes, cell transfer (Continued) 



homotransfer, of cells incubated in vitro, 

 107 



hypersensitivity, 101 



ami immunologic response, 103 



ami tissue transplantation immunity, 106 

 cells of, in vitro contact with antigen, 105 

 cervical, follicular lymphoma in, 190, 191 



in Hodgkin's disease, 232 

 Cortisol affecting, 121 

 dehydrogenases in, 45 



anil diphtheria antitoxin production, 104 

 draining sites of homografts, 101 

 enzyme activity in, 195, 199 

 follicles of, enzymes in, 195 



radiation affecting, 131 

 in follicular lymphoma, giant, 205 

 galactosidase in, 46 

 hematopoiesis in, 23 

 in Hodgkin's disease, 232-240 

 hyperplastic, phosphamidase in, 46 

 imprint preparations, 159, 169 

 inguinal, in hmphoblastoma, 179 

 in lymphatic leukemia, acute, 225 



chronic, 222 

 in lymphoblastoma, 178 

 lymphocyte turnover in. 69 

 in lymphosarcoma, 225, 258 

 mediastinal, in hmphoblastoma, 179 

 mesenteric, in feline malignant lymphoma, 

 174 



transferred cells, and antibody formation, 

 104 

 mesocolic, in lymphoma, 188 

 mitosis after radiation, 137 

 popliteal, transferred cells, 104, 108 

 radiation affecting, 130, 132, 137, 139 

 reconstituted, adrenocortical hormones af- 

 fecting, 119 

 smears, in diagnosis of disorders, 159, 169 

 sudanophilic granules in. 39 

 thoracic, in canine malignant lymphoma, 170 

 tissue fragments of, transplanted, 105 

 tumors arising in, 158 

 Lymphadenitis, in hmphoblastoma, 178 



tuberculous, cytochrome oxidase in. 46 

 Lymphadenopathy, in canine malignant lym- 

 phoma, 17<) 

 in follicular lymphoma, giant, 205, 212 

 in lymphatic leukemia, chronic, 212, 213, 216 

 in lymphocytic leukemia, chronic, 257 

 in lymphosarcoma, 225 

 L\mphangiosarcoma, follicular lymphoma with 



reticulum cell sarcoma after, 190 

 Lymphatic leukemia, acute, 225 



monocytic leukemia as variant of, 231 

 chronic, 212-225 



benign type, 213 



